AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01570036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
Study NCT01570036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
Study NCT01570036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeuVax vaccine
Description: At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
Study NCT01570036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
Study NCT01570036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
Study NCT02842606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test meal
Description: The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
Study NCT02842606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
Study NCT01690611 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Walking
Description: Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails.
Study NCT01690611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treadmill Walking
Description: Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails.
Study NCT01690611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: Real time feedback regarding body motion while walking.
Study NCT03811353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-MOE
Description: Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
Study NCT01647269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral GPi Deep Brain Stimulation
Description: Bilateral GPi Deep Brain Stimulation
Study NCT01676909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Well
Description: This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
Study NCT01676909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Illness Education & Support Group
Description: The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
Study NCT01498679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)
Description: ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
Study NCT01498679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered once daily in the evening via a NDPI
Study NCT00226031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Educational Material and Reminder
Description: Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
Study NCT00226031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Educational Material and Reminder
Description: Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
Study NCT03587974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH-VIETNAM
Description: Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
Study NCT02075268 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prasugrel
Description: prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
Study NCT02866084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device
Description: The following parameters will be set for active treatments using the CVS Device:~* A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~* The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies.
Study NCT03399487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378(Ceritinib)
Description: This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.
Study NCT03063112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency generator device
Description: sympathetic blockade or ablation of thoracic splanchnic nerves
Study NCT03063112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: sympathetic blockade or ablation of thoracic splanchnic nerves
Study NCT03063112 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: C arm fluoroscopic device
Description: sympathetic blockade or ablation of thoracic splanchnic nerves
Study NCT03063112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethyl alcohol
Description: sympathetic blockade or ablation of thoracic splanchnic nerves
Study NCT03979287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferential Current and Therapeutic Exercise Program
Description: The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises
Study NCT03979287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise Program
Description: The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~1. Ergonomic advices on reducing repetitive movements and/or maintained positions~2. A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises
Study NCT01198977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief telephone-based counseling
Description: Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
Study NCT01198977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education counseling
Description: Mailed informational video of exercise programs
Study NCT04041635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stimuli reduction
Description: Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
Study NCT04041635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
Study NCT01600716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
Study NCT01600716 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
Study NCT01600716 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (Normal Saline)
Description: Placebo (normal saline) is administered into the detrusor at Day 1.
Study NCT01940952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
Study NCT01940952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Donepezil 5mg or 10mg
Study NCT01940952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
Study NCT02121535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T80/A5 mg FDC tablet
Study NCT02121535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T80/A5 mg FDC tablet
Description: A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
Study NCT02121535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H12.5 mg tablet
Study NCT02121535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T80/A5/H12.5 ng FDC tablet
Description: A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
Study NCT02121535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H12.5 mf tablet
Description: A HCTZ 12.5 mg tablet
Study NCT02121535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T80/A5/H12.5 mg FDC tablet
Study NCT00698763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: from 0.125 mg to 2 mg in escalating doses
Study NCT00698763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical in appearance to active capsules
Study NCT02353208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Feeding of Bacon Bits
Description: Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
Study NCT02353208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will not be asked to chew bacon bits
Study NCT02106598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescent cRGDY-PEG-Cy5.5-C dots
Study NCT04029636 — intervention group
Intervention type: OTHER
Intervention: Inhaled Hyperpolarized Xenon-129
Description: How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
Study NCT02647619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiapex
Description: Injection of collagenase of primary dupytren cord
Study NCT02647619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle aponeurotomy
Description: 26 G needle multiple perforation tecqnique with local anesthetic
Study NCT03997344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group nature hikes
Description: Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
Study NCT03997344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group urban hikes
Description: Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
Study NCT04455438 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT dose escalation
Description: Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.
Study NCT03521284 — intervention group
Intervention type: OTHER
Intervention: Parental educational program
Description: Behavior: psychotherapy, life hygiene advice
Study NCT03521284 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: knowledge questionnaire + parental anxiety questionnaire
Study NCT01669837 — intervention group
Intervention type: DEVICE
Intervention: Mesh fixation with surgical tissue glue
Description: Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
Study NCT04318873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Promise Demonstration Benefits
Description: Monthly: Home-delivered food box, nutrition education handout, and $15 monthly voucher for fruits and vegetables
Study NCT03980054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib 400 mg, orally once daily for one year
Study NCT03980054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400mg, orally once daily for one year
Study NCT03638193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso cells
Description: CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m\^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
Study NCT00670254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application is identical to experimental arm
Study NCT00670254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
Study NCT02168244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heating Pack
Description: Application of heat to skin for 2-3 minutes prior to injection of biologic drug
Study NCT02168244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice pack
Description: Application of cold to skin for 2-3 minutes prior to injection of biologic drug
Study NCT04053777 — intervention group
Intervention type: DEVICE
Intervention: non-invasive ventilation
Description: Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
Study NCT01682889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
Study NCT01682889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9% intravenously for 24h
Study NCT03854266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose alteplase
Description: Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
Study NCT03854266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
Study NCT03854266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion catheter
Description: A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
Study NCT01792895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation
Description: The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
Study NCT01792895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization
Description: The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
Study NCT01792895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement
Description: This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions.
Study NCT02318706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Study NCT02318706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo